Drug
Gadopiclenol
Gadopiclenol: highest development phase Post-Market, developed by Guerbet. 7 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Guerbet
Trials
| Drug | Phase | Indication |
|---|---|---|
| Gadopiclenol NCT06226129 | Post-Market | Prostate Cancer |
| Gadopiclenol NCT06010173 | Phase 3 | Lesion in Body Region |
| gadopiclenol NCT03986138 | Phase 3 | Lesion in Body Region |
| gadopiclenol NCT03996447 | Phase 3 | CNS Lesion |
| gadopiclenol NCT07348640 | Phase 3 | Steno-occlusive Disease |
| Gadopiclenol NCT05590884 | Phase 2 | Central Nervous System Diseases |
| gadopiclenol NCT04906005 | Phase 1 | Pharmacokinetics |
Latest
No recent events.
Follow Gadopiclenol on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.